Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
02
2023
accepted:
21
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
Cyclooxygenase-2 plays a role in oncogenesis and its overexpression is associated with triple-negative breast cancer. However, the mechanisms whereby cyclooxygenase-2 contribute to breast cancer are complex and not well understood. Cyclooxygenase-2 overexpression causes hypoxia, oxidative stress, and endoplasmic reticulum stress. The aim of this study is to investigate the correlations among cyclooxygenase-2 expression, endoplasmic reticulum stress-associated molecules, and autophagy-associated molecules in triple-negative breast cancer. Surgical specimens from two cohorts of triple-negative breast cancer patients without neoadjuvant systemic therapy were analyzed: cohorts 1 and 2 consisted of 218 cases from 2004 to 2006 and 221 cases from 2007 to 2009, respectively. Specimens were evaluated by immunohistochemical examination of cyclooxygenase-2, endoplasmic reticulum stress markers, and autophagy markers expression using tissue microarrays. Cyclooxygenase-2 was overexpressed in 29.8% and 23.9% of cases in cohorts 1 and 2, respectively; and it was positively correlated with two out of three endoplasmic reticulum stress-associated molecules (XBP1, p = 0.025 and p = 0.003 in cohort 1 and cohort 2, respectively; PERK, p < 0.001 in both cohorts). Cyclooxygenase-2 was also positively correlated with two out of three autophagy markers (p62, p = 0.002 and p = 0.003 in cohort 1 and cohort 2, respectively; beclin1, p < 0.001 in both cohorts). Although cyclooxygenase-2 was not an independent prognostic factor for distant metastasis free survival and overall survival, its expression was associated with the expression of endoplasmic reticulum stress and autophagy molecules in triple-negative breast cancer.
Identifiants
pubmed: 37540709
doi: 10.1371/journal.pone.0289627
pii: PONE-D-23-05314
pmc: PMC10403079
doi:
Substances chimiques
Cyclooxygenase 2
EC 1.14.99.1
PTGS2 protein, human
EC 1.14.99.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289627Informations de copyright
Copyright: © 2023 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Oncogene. 2019 Aug;38(34):6184-6195
pubmed: 31312025
Ann Surg Oncol. 2014 May;21(5):1561-8
pubmed: 24385208
Hum Pathol. 2013 Oct;44(10):2180-7
pubmed: 23845466
Sci Rep. 2017 Jan 05;7:40258
pubmed: 28054666
Int J Mol Med. 2014 Sep;34(3):772-81
pubmed: 24970676
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Mol Clin Oncol. 2014 Sep;2(5):845-850
pubmed: 25054056
Cell Death Dis. 2016 Jun 02;7(6):e2251
pubmed: 27253415
Oncotarget. 2016 Sep 13;7(37):58953-58974
pubmed: 27270654
Cancer Lett. 2010 Sep 1;295(1):7-16
pubmed: 20381235
Biomed Pharmacother. 2020 Sep;129:110389
pubmed: 32540642
Pharmacol Res. 2022 Jan;175:106006
pubmed: 34843961
Cancers (Basel). 2018 Sep 21;10(10):
pubmed: 30248920
J Breast Cancer. 2017 Mar;20(1):65-73
pubmed: 28382096
Onco Targets Ther. 2013 Jul 19;6:883-8
pubmed: 23888115
Biomed Pharmacother. 2019 Oct;118:109249
pubmed: 31351428
J Biol Chem. 2004 Nov 5;279(45):46384-92
pubmed: 15319438
Cancer Manag Res. 2020 Jun 16;12:4595-4604
pubmed: 32606952
Histopathology. 2013 Jan;62(2):275-86
pubmed: 23134379
Ecotoxicol Environ Saf. 2019 Apr 15;170:112-119
pubmed: 30529609
Med Oncol. 2014 Jun;31(6):989
pubmed: 24816739
JAMA Oncol. 2021 Sep 01;7(9):1291-1301
pubmed: 34264305
J Cancer Res Clin Oncol. 2018 Mar;144(3):415-430
pubmed: 29288363
Cancer Res Treat. 2018 Jan;50(1):1-10
pubmed: 28903551
Cell Death Differ. 2007 Sep;14(9):1576-82
pubmed: 17612585
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Cancer Res. 2020 Jun 1;80(11):2368-2379
pubmed: 32265225
Cancer Metastasis Rev. 2018 Sep;37(2-3):355-368
pubmed: 30094570
Biochim Biophys Acta. 2012 Dec;1823(12):2179-89
pubmed: 22982228
Cancer Lett. 2012 Dec 1;325(1):63-71
pubmed: 22664238
Oncotarget. 2017 Jan 24;8(4):6003-6012
pubmed: 27999206